Biogen (BIIB) Q2 2024 earnings summary

Executive summary

• Q2 2024 total revenue was $2.5 billion, flat year-over-year at actual currency and up 1% at constant currency, with core pharmaceutical revenue up 5% and strong new product launches offsetting MS declines.

• GAAP diluted EPS was $4.00 (down 2% YoY); Non-GAAP diluted EPS was $5.28 (up 31% YoY), both including a $0.52/share benefit from a priority review voucher sale.

• Operating income increased 34% GAAP and 43% Non-GAAP; margins improved to 32% (GAAP) and 39% (Non-GAAP).

• Acquisition of HI-Bio for $1.15 billion completed in July 2024, expanding the immunology pipeline and expected to drive long-term growth.

• Cost base reduction, R&D prioritization, and Fit for Growth program are improving profitability and targeting $1 billion in gross savings by end of 2025.

Financial highlights

• Q2 2024 total revenue was $2.5 billion (+0.4% YoY); core pharmaceutical revenue grew 5% at actual currency and 6% at constant currency.

• Rare disease franchise revenue grew 22% (actual) to $534 million, with SKYCLARYS global revenue at $100 million.

• Non-GAAP diluted EPS grew 31% to $5.28, including a $0.52 one-time benefit from a priority review voucher sale; excluding this, EPS grew 18%.

• Free cash flow was $592 million for Q2 and $1.1 billion for the first half of 2024; cash and equivalents were $1.9 billion as of June 30, 2024.

• Net debt was $4.4 billion at quarter end.

Outlook and guidance

• Raised full-year 2024 Non-GAAP EPS guidance to $15.75–$16.25, reflecting ~9% growth at midpoint.

• Total revenue expected to decline by a low single-digit percentage versus 2023, with core pharmaceutical revenue roughly flat year-over-year.

• Operating income now expected to grow mid- to high-teens percent for 2024, with margin improvement.

• Anticipate higher expenses in the second half due to increased launch spending and R&D investment, including HI-Bio phase III starts.

• Guidance excludes impacts from future acquisitions, large business development, or litigation.